LAVA Therapeutics begins first-in-human Phase 1 study for LAVA-1266, targeting CD123 in AML and MDS patients.
Quiver AI Summary
LAVA Therapeutics has initiated a Phase 1 clinical trial for LAVA-1266, a bispecific anti-CD123 Gammabody® designed to treat adult patients with CD123-expressing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial, conducted in Australia, aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of LAVA-1266, with initial results expected by the end of 2025. LAVA-1266 targets CD123+ tumor cells while reportedly minimizing off-target effects and cytokine release, presenting a promising alternative to previous therapies. The study will involve approximately 50 patients receiving doses every two weeks, starting with an initial target dose of 100 µg for the first cohort. LAVA Therapeutics emphasizes the potential of this treatment based on encouraging preclinical results.
Potential Positives
- First patient dosed in the Phase 1, first-in-human study of LAVA-1266, marking a significant milestone for the company.
- LAVA-1266 has demonstrated a strong preclinical safety and efficacy profile, indicating its potential as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- The company anticipates initial Phase 1 data read-out by the end of 2025, suggesting a clear timeline for ongoing development and updates.
- The clinical study is being conducted in Australia and aims to evaluate approximately 50 adults with CD123+ relapsed/refractory AML or MDS, which could enhance the company's visibility and distribution partnerships in international markets.
Potential Negatives
- Initial Phase 1 data read-out is not expected until the end of 2025, indicating a long timeline before any potential therapeutic benefits can be assessed.
- The company's cautionary note on forward-looking statements emphasizes significant risks and uncertainties related to their clinical trials and product development, which may lead to disappointing outcomes.
- The reliance on preclinical results to support the therapeutic potential of LAVA-1266 could raise concerns, as past performance does not guarantee future success in clinical trials.
FAQ
What is LAVA-1266?
LAVA-1266 is a bispecific anti-CD123 Gammabody® designed to treat hematologic cancers like AML and MDS.
When did the LAVA-1266 study start?
The first patient was dosed in the Phase 1 study on January 10, 2025.
What results are expected from the LAVA-1266 trial?
Initial Phase 1 data read-out is anticipated by the end of 2025, evaluating safety and efficacy.
Where is the LAVA-1266 clinical study being conducted?
The clinical study of LAVA-1266 is currently taking place in Australia.
What types of patients are eligible for the LAVA-1266 study?
Adults with CD123+ relapsed/refractory acute myeloid leukemia and certain grades of myelodysplastic syndrome can participate.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LVTX Hedge Fund Activity
We have seen 7 institutional investors add shares of $LVTX stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SPHERA FUNDS MANAGEMENT LTD. removed 221,125 shares (-60.2%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 49,224 shares (-74.3%) from their portfolio in Q3 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 48,205 shares (+inf%) to their portfolio in Q3 2024
- TANG CAPITAL MANAGEMENT LLC added 47,992 shares (+939.4%) to their portfolio in Q3 2024
- PATHWAY FINANCIAL ADVISORS LLC added 42,500 shares (+70.8%) to their portfolio in Q3 2024
- XTX TOPCO LTD removed 30,807 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY added 20,800 shares (+133.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody
®
First-in-human study enrolling adult patients with CD123-expressing AML or MDS
Initial Phase 1 data read-out expected by year-end 2025
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) --
LAVA
Therapeutics
N.V.
(NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody
®
platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody
®
, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
“We are pleased to announce the dosing of the first patient with LAVA-1266, a potent and selective CD123-targeted Gammabody
®
. Based on the positive results of preclinical models showing tumor cell lysis with limited off-target effects, we believe that LAVA-1266’s preclinical safety and efficacy profile supports its potential as a treatment for AML and MDS,” said
Stephen Hurly, President and Chief Executive Officer
of LAVA Therapeutics. “We are eager to evaluate the safety, pharmacokinetics and pharmacodynamic properties and potential activity of LAVA-1266 and provide initial results from the dose escalation study by the end of the year.”
“CD123 is well-recognized as a potential therapeutic target for AML. However, the opportunity for earlier generations of CD123-targeted therapies has been limited by on-target, off-tumor toxicity, cytokine release syndrome and capillary leak syndrome,” said
Charles Morris, MD, Chief Medical Officer
of LAVA Therapeutics. “We are enthusiastic about LAVA-1266 based on its strong preclinical profile, and we look forward to working with our clinical study sites in Australia.”
About LAVA-1266
LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody
®
platform. The bsTCE was designed to lyse CD123+ tumor cells with high potency and a wide therapeutic window.
Preclinical studies confirmed target cell expression by showing CD123+ expression and the presence of Vγ9Vδ2-T cells in AML patient samples. In preclinical studies, LAVA showed that LAVA-1266 preferentially targets and kills CD123 cells and induces Vγ9Vδ2-T cell activation. Furthermore, in preclinical studies, LAVA demonstrated that treatment with LAVA-1266 produces high levels of specific tumor cell lysis, with substantially less cytokine release, compared to CD3-based T cell engagers, and increased survival in an AML xenograft model, without the co-activation of immunosuppressive regulatory T cells.
About the Phase 1 First-in-human Study of LAVA-1266 (ACTRN12624001214527)
The open-label, multi-center Phase 1, first-in-human study of LAVA-1266 is currently being conducted in Australia. The study will include a dose escalation and dose expansion segment to evaluate LAVA-1266 in approximately 50 adults with CD123+ relapsed/refractory acute myeloid leukemia (AML) and certain grades of myelodysplastic syndrome (intermediate risk, high risk or extremely high risk). Patients will be dosed every two weeks (Q2W), with an initial target dose of 100 µg for the first cohort.
The study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary anti-tumor activity.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody
®
platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.
LAVA’s pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at
www.lavatherapeutics.com
, or follow us on
LinkedIn
,
X
, and
YouTube
.
Gammabody
®
is a registered trademark of LAVA Therapeutics N.V.
LAVA’s
Cautionary
Note
on
Forward-Looking
Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “could”, “will”, “may”, “expect”, “should”, “plan”, “intend”, “estimate”, “potential”, “suggests”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements relating to the therapeutic potential, development strategy and potential uses of LAVA’s product candidates, including LAVA-1266, the timing of initiation of clinical trials and achievement of clinical milestones, LAVA’s cash runway and the sufficiency of resources to pursue development activities, progress and data from clinical trials, and the ability of LAVA’s product candidates to treat various tumor targets and improve patient outcomes. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, the Company’s ability to leverage its initial programs to develop additional product candidates using its Gammabody
®
platform, the failure of LAVA’s collaborators to support or advance collaborations or LAVA’s product candidates, the timing and results of LAVA’s research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, the Company’s ability to obtain regulatory approval for and commercialize its product candidates, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on the Company’s business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including between Russia and escalating tension in the Middle East. These and other risks are described in greater detail under the caption “Risk Factors” in LAVA’s most recent Annual Report on Form 20-F and other filings the Company makes with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACTS
Investor Relations
ir@lavatherapeutics.com
LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
